Merck's Overvaluation and Dividend Concerns Worry Investors

Merck & Co Inc (NYSE: MRK) recently received a positive regulatory update as the European Medicines Agency's Committee for Medicinal Products for Human Use gave a favorable opinion on the approval of Keytruda in combination with Padcev for muscle-invasive bladder cancer.

The development comes as investors weigh Merck's dividend sustainability and valuation metrics. The company offers a dividend yield of 2.3% with a payout ratio of 1.05, indicating a payout that may not be sustainable despite a 3-year dividend growth rate of 5.4%.

According to GuruFocus' proprietary GF Value™ metric, the stock is currently modestly overvalued by 22.5%, with an intrinsic value estimated at $120.15 per share compared to the current market price of $147.15.